Hepatitis C cannot be eliminated in the United States without reaching groups that are most impacted by the epidemic. Incarcerated or formerly incarcerated individuals bear a disproportionate burden of HCV with current estimates putting the prevalence in jails and prisons between 12 and 35 percent. Despite the high prevalence and recommendations from the Federal Bureau of Prisons (FBoP), the American Association for the Study of Liver Diseases (AASLD), and the Infectious Diseases Society of America (IDSA) to offer opt-out antibody testing (at the very least) to all incarcerated individuals, most inmates with chronic HCV are unaware of their status. Screening and linking individuals to care while incarcerated or upon release is essential to ensure they have access to a cure.
Join NASTAD’s Hepatitis Testing Partnership and the National Hepatitis Corrections Network for a webinar to explore strategies for HCV testing and linkage to care for people currently in or transitioning from prison. Please feel free to share this webinar with anyone in your network who might be interested, particularly partners who work in or with departments of correction.